Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma - PubMed
4 days ago
- #multiple myeloma
- #pre-emptive treatment
- #daratumumab
- The PREDATOR-BR trial studied daratumumab vs. observation in asymptomatic biochemical relapse of multiple myeloma.
- Daratumumab significantly improved event-free survival (28.9 months vs. 4.0 months) and overall survival (100% vs. 70.5% at 24 months).
- Response rate was 61.0% with daratumumab compared to 6.8% with observation.
- Treatment was safe and did not negatively impact quality of life.
- Early treatment during biochemical relapse may delay clinical relapse and prolong survival.